Disposition of Oral Nalbuphine and Its Metabolites in Healthy Subjects and Subjects with Hepatic Impairment: Preliminary Modeling Results Using a Continuous Intestinal Absorption Model with Enterohepatic Recirculation

• Published in: Metabolites Vol. 14; no. 9; p. 471
• Main Authors: Nagar, Swati, Hawi, Amale, Sciascia, Thomas, Korzekwa, Ken
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.09.2024; MDPI
• Subjects: Analgesics; Bioavailability; Comparative analysis; Differential equations; Drug dosages; Drug interaction; drug metabolism; enterohepatic recycling; Enzymes; hepatic impairment; Intestinal absorption; Intestine; Isoenzymes; Liver; mechanistic modeling; Metabolism; Metabolites; Nalbuphine; Oral administration; Partial differential equations; Pharmacokinetics; Physiological aspects; Plasma; Proteins; United States > US; hepatic impairment; pharmacokinetics; enterohepatic recycling; nalbuphine; mechanistic modeling; drug metabolism
• DOI: 10.3390/metabo14090471
• ISSN: 2218-1989

Nalbuphine (NAL) is a mixed κ-agonist/μ-antagonist opioid with extensive first-pass metabolism. A phase 1 open-label study was conducted to characterize the pharmacokinetics (PKs) of NAL and select metabolites following single oral doses of NAL extended-release tablets in subjects with mild, moderate, and severe hepatic impairment (Child–Pugh A, B, and C, respectively) compared to healthy matched subjects. NAL exposures were similar for subjects with mild hepatic impairment as compared to healthy subjects and nearly three-fold and eight-fold higher in subjects with moderate and severe hepatic impairment, respectively. Datasets obtained for healthy, moderate, and severe hepatic impaired groups were modeled with a mechanistic model that incorporated NAL hepatic metabolism and enterohepatic recycling of NAL and its glucuronidated metabolites. The mechanistic model includes a continuous intestinal absorption model linked to semi-physiological liver–gallbladder–compartmental PK models based on partial differential equations (termed the PDE-EHR model). In vitro studies indicated that cytochromes P450 CYP2C9 and CYP2C19 are the major CYPs involved in NAL oxidation, with glucuronidation mainly catalyzed by UGT1A8 and UGT2B7 isozymes. Complex formation and elimination kinetics of NAL and four main metabolites was well predicted by PDE-EHR. The model is expected to improve predictions of drug interactions and complex drug disposition.